No­var­tis to buy siR­NA de­vel­op­er DTx Phar­ma for up to $1B

No­var­tis will con­tin­ue to add siR­NA ca­pa­bil­i­ties to its tool belt in a deal worth up to $1 bil­lion.

The Swiss phar­ma ac­quired DTx Phar­ma, a San Diego-based biotech with a siR­NA ther­a­py that it wants to start test­ing in pa­tients with Char­cot-Marie-Tooth dis­ease Type 1A (CMT1A), a neu­ro­mus­cu­lar dis­ease that can cause loss of mus­cle func­tion.

There are about 150,000 pa­tients with CMT1A in the US and Eu­rope.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER